References
- Klein-Schwartz W, Benson BE, Lee SC, et al. Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children. Clin Toxicol. 2012;50:418–423.
- Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin uptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:315–332.
- Viibryd (Vilazodone) [Internet]. Prescribing information [revised 2016 Aug]. Allergan [cited 2016 Aug 31]. Available from: http://www.allergan.com/assets/pdf/viibryd_pi
- US Food and Drug Administration [Internet]. Clinical Pharmacology and Biopharmaceuticals review [cited 2016 Aug 31]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf
- Sahil ZT, Banerjee P, Tarazi FI. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov. 2016;11:515–523.
- Wang SM, Han C, Lee SJ, et al. Vilazodone for the treatment of depression: an update. Chonnam Med J. 2016;53:91–100.
- Acker EC, Sinclair EA, Beardsley AL, et al. Acute vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49:284–286.
- Carstairs SD, Griffith EA, Alayin T, et al. Recurrent seizure activity in a child after acute vilazodone ingestion. Ann Emerg Med. 2012;60:819–820.
- Mowry JB, Spyker DA, Brooks DE, et al. 2014 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol. 2015;53:962–1147.
- Jaramillo JE, Marchbanks B, Willis B, et al. Evaluation of completeness of selected poison control center data fields. J Med Syst. 2010;34:499–507.